Residency · Residency · Chronic Pain Management
Lumbar Sympathetic Block
Introduction
The lumbar sympathetic block targets the lumbar sympathetic chain to interrupt sympathetic innervation to the lower extremity. It is a critical diagnostic and therapeutic tool for sympathetically maintained pain (SMP) in the lower extremity, most commonly associated with complex regional pain syndrome (CRPS), as well as peripheral vascular disease and other sympathetically mediated conditions. Because the lumbar sympathetic chain is anatomically distinct from somatic nerves, selective sympathetic blockade can be achieved without producing motor or sensory deficits.
Anatomy of the Lumbar Sympathetic Chain
The lumbar sympathetic chain consists of 4-5 ganglia located along the anterolateral aspect of the lumbar vertebral bodies, within the retroperitoneal space anterior to the psoas muscle fascia. On the right side, the chain sits anterolateral to the vertebral body and is partially covered by the inferior vena cava. On the left side, it lies along the anterolateral border of the vertebral body, lateral to the aorta.
Preganglionic fibers originate from the T10-L2 (or L3) intermediolateral cell column of the spinal cord and descend through the thoracic sympathetic chain to synapse in the lumbar ganglia. Postganglionic fibers then travel with the lumbar somatic nerves and the femoral, obturator, and sciatic nerves to supply sympathetic innervation to the lower extremity vasculature, skin, and sweat glands. The L2 or L3 level is the most commonly targeted because a single-level block at this level can effectively block sympathetic outflow to the entire lower extremity, thanks to the interconnected chain.
<image>Anterolateral anatomical illustration of the lumbar spine showing the lumbar sympathetic chain with its ganglia draped along the anterolateral surface of the L1-L5 vertebral bodies. The illustration shows the chain's relationship to the psoas major muscle (retracted laterally), the aorta and inferior vena cava. Rami communicantes connecting the sympathetic chain to the lumbar spinal nerves are depicted. A needle is shown approaching the L3 vertebral body from a posterolateral trajectory, with its tip resting at the anterolateral border of the vertebral body in the correct position for sympathetic blockade.</image>
Indications
The primary indication is CRPS types I and II of the lower extremity, both for diagnostic confirmation of SMP and for therapeutic relief. Other indications include peripheral vascular disease with rest pain, non-healing ulcers, or vasospasm (Raynaud phenomenon of the lower extremity); phantom limb pain following lower extremity amputation; herpes zoster and postherpetic neuralgia involving lumbar dermatomes; hyperhidrosis of the lower extremity (a rare indication); and frostbite of the lower extremity to improve vascular perfusion.
Fluoroscopic Technique
Patient Positioning and Approach
The patient is positioned prone on a fluoroscopy table. The fluoroscope is rotated to an oblique view (approximately 15-20 degrees) to visualize the anterolateral border of the target vertebral body, typically L2 or L3. A 22-gauge, 15 cm spinal needle is advanced under fluoroscopic guidance toward the anterolateral margin of the L3 vertebral body.
Needle Placement
In the oblique view, the needle trajectory passes lateral to the transverse process and aims for the anterior one-third of the vertebral body. The needle is advanced until contact is made with the vertebral body, then walked off anterolaterally until the tip reaches the anterolateral border. On lateral fluoroscopy, the needle tip should be positioned at the anterior one-third of the vertebral body, confirming an anterolateral position in the retroperitoneal space. The AP view confirms the needle tip is at or just beyond the lateral border of the vertebral body.
Injection
After negative aspiration (to exclude vascular, ureteral, or intrathecal placement), 1-2 mL of contrast is injected. The contrast should spread in a craniocaudal longitudinal pattern along the anterolateral aspect of the vertebral bodies, confirming paravertebral sympathetic chain location. The lateral view confirms contrast remaining anterior to the psoas fascia and not spreading posteriorly toward the epidural or somatic nerve region. Then 10-15 mL of local anesthetic (0.25% bupivacaine or 1% lidocaine) is injected incrementally after confirming appropriate spread.
<image>Fluoroscopic image illustration showing lumbar sympathetic block at L3. The AP view demonstrates the needle tip at the anterolateral border of the L3 vertebral body with contrast dye spreading in a linear, craniocaudal pattern along the anterolateral vertebral bodies from L2 to L4. The lateral view shows the needle tip at the anterior one-third of the L3 vertebral body with contrast remaining anterior to the psoas muscle plane. Anatomic landmarks including the transverse processes, pedicles, and vertebral body margins are labeled.</image>
Confirmation of Successful Block
A successful sympathetic block is confirmed by a temperature increase of at least 1-2 degrees Celsius in the ipsilateral foot (measured by skin thermometry or thermography), abolition of the skin conductance response on the ipsilateral foot, and visible vasodilation of the ipsilateral lower extremity (plethysmographic changes, skin color change). Critically, the absence of somatic nerve blockade — preserved motor strength and light touch sensation — confirms that the block is selective for the sympathetic chain.
Neurolytic Lumbar Sympathetic Block
Indications
Neurolytic blockade is considered for refractory CRPS that has demonstrated consistent response to diagnostic local anesthetic blocks but requires repeated procedures, inoperable peripheral vascular disease with rest pain and non-healing ulcers, and patients who obtain reliable but short-duration relief from local anesthetic blocks.
Agents and Technique
The two most commonly used neurolytic agents are phenol (6-8%) and absolute alcohol (50-100%). Phenol is self-limiting due to its local anesthetic properties and produces protein denaturation and Wallerian degeneration. Alcohol produces more complete and longer-lasting neurolysis but causes severe burning pain on injection, necessitating pre-injection of local anesthetic. The typical volume for neurolysis is 3-5 mL per level, and contrast spread should be confirmed before switching to the neurolytic agent. Duration of neurolysis is generally 3-6 months before nerve regeneration occurs. Chemical sympathectomy via neurolysis has largely replaced open surgical sympathectomy.
| Agent | Concentration | Mechanism | Pain on Injection | Duration | Advantages |
|---|---|---|---|---|---|
| Phenol | 6-8% | Protein denaturation, Wallerian degeneration | Minimal (local anesthetic properties) | 3-6 months | Self-limiting; less painful |
| Absolute alcohol | 50-100% | Extraction of lipids, protein precipitation | Severe burning (requires pre-LA) | 3-6 months (may be longer) | More complete neurolysis |
Risks Specific to Neurolysis
Genitofemoral neuralgia — groin pain and paresthesia — is the most common complication of neurolytic lumbar sympathetic block, occurring in up to 5-10% of cases. Ureteral injury is a risk, particularly on the right side. Bilateral neurolysis carries a risk of ejaculatory dysfunction.
Complications
Complications include groin pain and genitofemoral neuralgia from spread of anesthetic or neurolytic agent to the genitofemoral nerve or L1 somatic root, intravascular injection into the aorta, IVC, or segmental vessels, ureteral puncture (more common on the right side), discitis or vertebral body osteomyelitis (rare), retroperitoneal hematoma from vascular puncture, orthostatic hypotension from bilateral sympatholysis (bilateral simultaneous blocks should be avoided), and somatic nerve block indicating posterior needle placement or excessive volume spreading to the psoas compartment.
Clinical Pearls
The L3 level is the optimal target for a single-needle technique because the interconnected chain at this level provides sympathetic blockade to the entire lower extremity in most patients. On lateral fluoroscopy, the needle tip must be at the anterior one-third of the vertebral body — a posterior position risks somatic nerve blockade in the psoas compartment. The contrast spread pattern is the single most important safety and efficacy confirmation; it must be linear and craniocaudal, not posterior or lateral. Before proceeding to neurolytic blocks, always perform two or more diagnostic local anesthetic blocks first to confirm consistent sympathetically maintained pain. Patients should be counseled preoperatively about the risk of genitofemoral neuralgia following neurolysis, as it can be persistent and distressing.
References
- Haynsworth RF Jr, Noe CE. Percutaneous lumbar sympathectomy: a comparison of radiofrequency denervation versus phenol neurolysis. Anesthesiology. 1991;74(3):459-463.
- Manchikanti L, Kaye AD, Falco FJ, Hirsch JA. Essentials of interventional techniques in managing chronic pain. Springer. 2018; Chapter on Lumbar Sympathetic Blocks.
- Boas RA. Sympathetic nerve blocks: in search of a role. Reg Anesth Pain Med. 1998;23(3):292-305.
- Straube S, Derry S, Moore RA, Cole P. Cervico-thoracic or lumbar sympathectomy for neuropathic pain and complex regional pain syndrome. Cochrane Database Syst Rev. 2013;(9):CD002918.
